Metastatic or recurrent tumors are the primary cause of cancer‐related death. For prostate
cancer, patients diagnosed with local disease have a 99% 5‐year survival rate; however …

Tissue transglutaminase (TG2) catalyzes the cross-linking of proteins by the formation of
isopeptide bonds between glutamine (Gln) and lysine (Lys) side chains. Although TG2 is …

Recent studies indicate that cancer cells express elevated levels of type II transglutaminase
(TG2), and that expression is further highly enriched in cancer stem cells derived from these …

Abstract Transglutaminase 2 (TG2) expression is required for epidermal squamous cell
carcinoma cancer stem cell survival. However, the molecular signaling mechanisms …

Transglutaminase 2 (TG2) has emerged as a key cancer cell survival factor that drives
epithelial to mesenchymal transition, angiogenesis, metastasis, inflammation, drug …

The major barrier to a HIV-1 cure is the persistence of latent genomes despite treatment with
antiretrovirals. To investigate host factors which promote HIV-1 latency, we conducted a …

Simple Summary Transglutaminase-2 (TG2) is an enzyme primarily involved in protein cross-
linking, which has been shown to play a role in the development and progression of …

Despite decades of research and successful improvements in diagnosis and therapy,
prostate cancer (PC) remains a major challenge. In recent years, it has become clear that …

Cisplatin (CDDP)-based combination chemotherapy remains the mainstream treatment for
advanced bladder cancer. However, its efficacy is often limited due to the development of …

The ability of cancer cells to metastasize represents the most devastating feature of cancer.
Currently, there are no specific biomarkers or therapeutic targets that can be used to predict …